1) Technically there are very few shares offered at this level. One verity in the stock market is that there has to be a substantial supply of stock available for purchase before large buyers will enter the market. So I am happy with Reynolds' and Langer's repeated sales.
Approval is expected soon by FDA to begin the first clinical trial and this will act as a catalyst for the share price.
3) Results of this trial will become public in a short time since there will only be five subjects.
4) Frank Reynolds - bless his heart - will continue to promote the company's prospects.